Table 4.
Mutant allele fraction (MAF) of KRAS and NRAS, overall and stratified according to the main demographic, clinical, and therapeutic features.
| MAF KRAS
(Median, IQR) |
p-Value § | MAF NRAS
(Median, IQR) |
p-Value § | |||
|---|---|---|---|---|---|---|
| Overall | n = 55 | 0.16 (IQR 0.01–4.79; range 0–28.15) | n = 61 | 0.007 (IQ1 0.003–0.010; range 0.001–0.516) | ||
| Demographics | ||||||
| Male sex | n = 23 | 0.22 (0.01–5.46) | 0.511 | n = 34 | 0.006 (0.003–0.009) | 0.425 |
| Female sex | n = 32 | 0.06 (0.01–2.05) | n = 27 | 0.007 (0.002–0.014) | ||
| Histology | ||||||
| ADK | n = 48 | 0.17 (0.02–3.90) | 0.990 | n = 54 | 0.006 (0.002–0.008) | 0.004 * |
| Colloid ADK | n = 7 | 0.05 (0.01–13.0) | n = 7 | 0.027 (0.009–0.310) | ||
| Grading | ||||||
| G2 | n = 242 | 0.49 (0.02–7.37) | 0.025 * | n = 25 | 0.005 (0.003–0.010) | 0.828 |
| G3 | n = 8 | 0.01 (0.01–0.14) | n = 11 | 0.007 (0.002–0.011) | ||
| G4 | n = 1 | 0.00 | n = 1 | 0.006 | ||
| Missing | n = 22 | 0.25 (0.03–3.10) | n = 24 | 0.007 (0.004–0.009) | ||
| Site of primary lesion | ||||||
| Colon | n = 43 | 0.22 (0.01–5.46) | 0.660 | n = 45 | 0.007 (0.003–0.010) | 0.189 |
| Rectal | n = 8 | 0.06 (0.04–0.60) | n = 10 | 0.007 (0.003–0.010) | ||
| Transverse colon | n = 2 | 0.04 (0.01–0.06) | n = 2 | 0.002 | ||
| Missing | n = 2 | 1.62 (1.62–3.10) | n = 4 | 0.007 (0.005–0.007) | ||
| Staging | ||||||
| IV (new diagnosis) | n = 20 | 0.71 (0.04–9.01) | 0.330 | n = 20 | 0.008 (0.006–0.105) | 0.575 |
| IV (relapse) | n = 12 | 0.48 (0.01–5.07) | n = 14 | 0.011 (0.004–0.030) | ||
| Missing | n = 23 | 0.06 (0.01–0.33) | n = 27 | 0.004 (0.002–0.007) | ||
| Number of metastases | ||||||
| 1 | n = 26 | 0.23 (0.01–1.00) | 0.776 | n = 28 | 0.005 (0.002–0.008) | 0.243 |
| 2 | n = 21 | 0.06 (0.01–7.66) | n = 23 | 0.007 (0.003–0.010) | ||
| 3+ | n = 8 | 0.15 (0.04–5.07) | n = 10 | 0.007 (0.004–0.014) | ||
| Site of metastasis | ||||||
| Liver | No: n = 22; Yes: n = 33 | No: 0.05 (0.01–0.44) Yes: 0.33 (0.02–6.76) |
0.049 * | No: n = 24; Yes: n = 37 | No: 0.005 (0.003–0.007) Yes: 0.007 (0.003–0.13) |
0.061 |
| Lung | No: n = 41; Yes: n = 14 | No: 0.05 (0.07–0.77) Yes: 0.96 (0.04–5.61) |
0.113 | No: n = 43; Yes: n = 18 | No: 0.005 (0.002–0.009) Yes: 0.008 (0.006–0.017) |
0.025 * |
| Loco-regional | No: n = 45; Yes: n = 10 | No: 0.16 (0.01–5.26) Yes: 0.24 (0.02–1.00) |
0.785 | No: n = 49; Yes: n = 12 |
No: 0.007 (0.003–0.011) Yes: 0.007 (0.003–0.007) |
0.315 |
| Lymph nodes | No: n = 43; Yes: n = 12 | No: 0.16 (0.01–1.00) Yes: 0.23 (0.01–6.11) |
0.514 | No: n = 50; Yes: n = 11 | No: 0.006 (0.002–0.009) Yes: 0.009 (0.004–0.014) |
0.100 |
| Peritoneum | No: n = 43; Yes: n = 12 | No: 0.32 (0.01–5.26) Yes: 0.05 (0.01–0.15) |
0.139 | No: n = 50; Yes: n = 11 | No: 0.007 (0.003–0.009) Yes: 0.007 (0.002–0.056) |
0.799 |
| Bone | No: n = 53 Yes: n = 2 |
No: 0.16 (0.01–4.69) Yes: 0.09 (0.01–0.17) |
- | No: n = 59 Yes: n = 2 |
No: 0.007 (0.003–0.010) Yes: 0.04 (0.004–0.004) |
- |
| Surgery on primary site | ||||||
| Yes | n = 42 | 0.06 (0.01–0.92) | 0.010 * | n = 47 | 0.008 (0.006–0.010) | 0.126 |
| No | n = 13 | 5.46 (0.07–9.86) | n = 14 | 0.006 (0.002–0.010) | ||
| Chemotherapy | ||||||
| No | n = 1 | 0.01 | - | n = 1 | 0.007 | - |
| Yes (any) | n = 42 | 0.17 (0.01–5.26) | n = 47 | 0.007 (0.003–0.010) | ||
| Only synthetic agents | n = 14 | 0.36 (0.01–8.16) | 0.359 ** | n = 17 | 0.007 (0.005–0.007) | 0.343 ** |
| Only targeted biologics | n = 4 | 0.02 (0.01–0.12) | n = 5 | 0.013 (0.011–0.469) | ||
| Combination of synthetic and biologics | n = 24 | 0.17 (0.01–3.13) | n = 25 | 0.005 (0.002–0.10) | ||
| Missing | n = 12 | 0.25 (0.04–3.90) | n = 13 | 0.006 (0.002–0.009) | ||
| Response | ||||||
| Complete response | n = 3 | 0.01 (0.01–0.02) | 0.160 | n = 3 | 0.011 (0.004–0.469) | 0.552 |
| Partial response | n = 4 | 0.03 (0.00–3.58) | n = 4 | 0.006 (0.004–0.007) | ||
| Stable disease | n = 6 | 0.09 (0.01–0.23) | n = 8 | 0.006 (0.003–0.012) | ||
| Progressive disease | n = 17 | 0.44 (0.03–1.00) | n = 20 | 0.007 (0.003–0.010) | ||
| TE | n = 7 | 0.33 (0.16–3.10) | ||||
| Missing | n = 18 | 0.11 (0.01–5.46) | n = 18 | 0.005 (0.002–0.008) | ||
| Survival | ||||||
| Survived | n = 22 | 0.11 (0.01–0.39) | 0.459 | n = 25 | 0.004 (0.002–0.007) | 0.182 |
| Deceased | n = 9 | 0.22 (0.01–8.16) | n = 11 | 0.007 (0.003–0.009) | ||
| Missing | n = 24 | 0.53 (0.02–6.18) | n = 25 | 0.008 (0.004–0.017) |
§ excluding missing values; * statistically significant for p < 0.05. ** p-values are referred to the comparison between the three chemotherapy approaches (only synthetic agents, only targeted biologics, and their combination).